Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03980808 · ClinicalTrials.gov registry record · NA
American Sign Language-Accessible Diabetes Education
A NA study, sponsored by Georgia Institute of Technology.
- Completed
- Registry status
- NA
- Development phase
- 41
- Enrollment target
NCT03980808: Completed NA study, sponsored by Georgia Institute of Technology.
NCT03980808 is a NA study that has completed, run by Georgia Institute of Technology. The registered enrollment target is 41 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03980808, a NA study, has completed, sponsored by Georgia Institute of Technology.
- COMPLETED
- Registry status
- NA
- Development phase
- 41 participants
- Enrollment target
Study Summary
ASL-ADE will evaluate the efficacy of an ASL-interpreted diabetes educational intervention to the end of improving the health literacy of the target population and addressing their disparate health outcomes.
Primary Outcome
Data were collected using a study-specific, knowledge-based Diabetes Health Literacy measure which included 15 forced-choice, closed-ended questions to allow for a total score ranging from 0 to 15, with higher scores reflecting better diabetes health literacy. Analysis of change of knowledge compared differences between the intervention arm and the control arm as measured by the changes to the composite scores of the knowledge-based test. One factor Analysis of Variance (ANOVA) was used to calcu
Interventions
- BEHAVIORAL Control Intervention
- BEHAVIORAL American Sign Language-Accessible Diabetes Education
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2020-10-29 |
| Est. Completion | 2021-01-26 |
| Phase | NA |
What the finished NCT03980808 record still lists
NCT03980808 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Control Intervention is the first listed.
NCT03980808 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03980808 about?
NCT03980808 is a clinical study titled "American Sign Language-Accessible Diabetes Education". ASL-ADE will evaluate the efficacy of an ASL-interpreted diabetes educational intervention to the end of improving the health literacy of the target population and addressing their disparate health outcomes.
What is the current status of trial NCT03980808?
This trial is currently completed. It is a NA study. The enrollment target is 41 participants. The study started on 2020-10-29. Estimated completion is 2021-01-26.
What interventions are being tested in trial NCT03980808?
The interventions under investigation include: Control Intervention (BEHAVIORAL), American Sign Language-Accessible Diabetes Education (BEHAVIORAL).
Who is sponsoring clinical trial NCT03980808?
This trial is sponsored by Georgia Institute of Technology, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03980808's enrollment target sits among peer trials
41 1446th of 2000 higher than 554 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI